MEDtalk: First new drug in years reduces recurrence in high-risk hormone receptor positive early breast cancer

Stephen Johnston | Syys 2020 | ESMO 2020 |

Stephen Johnston
Professor,
The Royal Marsden Hospital
NHS Foundation Trust,
London

Adding abemaciclib to hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer. In this MEDtalk Professor Stephen Johnston, from the Royal Marsden Hospital NHS Foundation Trust, London, presents the new data presented at ESMO 2020.